Navigation Links
Sanofi-Aventis Recognized for Workplace Efforts to Prevent Cancer

BRIDGEWATER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has received CEO Cancer Gold Standard(TM) accreditation from the non-profit organization CEO Roundtable on Cancer, in recognition of the company's extensive efforts to encourage employees at all U.S. facilities (sanofi-aventis U.S. and sanofi pasteur) to take an active role in their health and reduce their risks of developing cancer. The CEO Cancer Gold Standard is awarded to companies that have met exceptionally high standards of cancer prevention, screening and care in the workplace through concrete action in five defined areas. With this accreditation, sanofi-aventis becomes the 34th company to be granted this honor since the program's inception in 2006.

"We are proud to be recognized by the CEO Roundtable on Cancer for our steadfast dedication to cancer prevention and improved cancer care," said Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. "For more than 50 years, sanofi-aventis has worked to improve the lives of patients with cancer - not only through our strategic focus on the research and discovery of new therapeutic approaches in oncology, but also through our support and efforts to improve the health and wellness of our employees and their families."

To earn Gold Standard accreditation, an organization must establish programs to reduce cancer through: (1) discouraging tobacco use; (2) encouraging physical activity; (3) encouraging healthy diet and nutrition; (4) detecting cancer at its earliest stages; and (5) providing access to quality care and clinical trials. Programs established under the guidance of the CEO Roundtable on Cancer help reduce cancer mortality, and statistics show that the efforts recognized by the Gold Standard have a tangible impact on the cost of treating cancer, which totaled nearly $210 billion in 2005 in the U.S., according to the Centers for Disease Control and Prevention.

"Our Gold Standard certification acknowledges the commitment to health and wellness made by sanofi-aventis, as well as the specific programs developed with its own employees and family members in the U.S.," said William C. Weldon, chairman and chief executive officer of Johnson & Johnson, and chair of the CEO Roundtable on Cancer. "Through the leadership of global CEO Christopher Viehbacher, sanofi-aventis has demonstrated its unwavering dedication to fighting cancer - and we are pleased to welcome them into the ranks of this select group."

Sanofi-aventis's progressive health and cancer prevention efforts in the U.S. include tobacco-free campuses as of November 19th, 2009; free screening programs for skin and prostate cancer; mammogram scheduling assistance and distribution of breast self-exam cards; and CancerConnect, a new employee support program that provides employees with resources and support to help navigate the journey of their own or a loved one's cancer diagnosis. The company's recent donation of chemotherapy products to the Foundation for the National Institutes of Health for clinical trial use, its continued sponsorship of the cancer awareness initiative Kaleidoscope (formerly known as Frosted Pink) as well as many other cancer education and awareness programs further underscore this accreditation.

The Gold Standard accreditation puts sanofi-aventis in the company of the following organizations also recognized as championing workplace-based efforts to eliminate cancer as a public health threat: American Cancer Society, American Legacy Foundation, AstraZeneca, C-Change, CIGNA, Dana-Farber Cancer Institute, Duke Medicine, Edelman, Enzon Pharmaceuticals, GHI, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, Millennium: The Takeda Oncology Company, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute (NCI), Novartis, The Oncology Nursing Society, OSI Pharmaceuticals, Pfizer, PhRMA, PPD, Quintiles Transnational, SAS Institute, The University of North Dakota, US Oncology, Valeant Pharmaceuticals, Vanderbilt-Ingram Cancer Center, Virtua Health and The Wistar Institute.

About the CEO Roundtable on Cancer

The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded with the CEO Cancer Gold Standard encouraging its widespread adoption in workplaces across the country. For more information on the CEO Cancer Gold Standard(TM) and the accreditation process, please visit

About sanofi-aventis

Sanofi-aventis is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information,

    Noelle Boyd
    sanofi-aventis U.S.

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
2. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
3. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
4. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
5. TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement
6. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
7. Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
8. Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
9. Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
10. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
11. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: